TXG stock forecast, quote, news & analysis
10x Genomics Inc is a life science technology company based in the United States... Show more
Why 10x Genomics (TXG) Stock Is Up +44% in the Last 30 Days
Key Takeaways
- 10x Genomics (TXG) shares climbed roughly 44% over the last 30 days, rising from about $62.45 to $90.04 as of the most recent close.
- The advance extends a powerful multi-month rally, with the stock more than doubling over the last quarter.
- Key catalysts include the first commercial shipments of the Atera spatial biology platform, a patent-infringement verdict against Parse Biosciences, and a series of analyst rating and price-target increases.
- Investor enthusiasm is also tied to growing demand for large-scale biological datasets used to train AI models of biology.
- The shares trade near a 52-week high, while average analyst price targets remain below the current price, underscoring an active valuation debate.
10x Genomics (TXG) Company Overview and Market Position
10x Genomics is a life science technology company that develops instruments, consumables, and software for analyzing biological systems at single-cell and spatial resolution. Headquartered in Pleasanton, California, the company sells integrated solutions built around its Chromium single-cell platform, the Visium spatial platform, the Xenium in situ imaging platform, and the recently introduced Atera platform for whole-transcriptome spatial analysis at scale.
The company's razor-and-blade business model pairs instrument placements with recurring consumables and software revenue, serving academic researchers, translational scientists, and biopharmaceutical customers worldwide. Investors follow TXG closely because its platforms sit at the intersection of genomics and artificial intelligence, producing the high-quality biological datasets increasingly used to train foundation models and "virtual cell" systems.
10x Genomics (TXG) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, TXG advanced from a closing price of $62.45 on August 31, 2026, to $90.04 as of the most recent close, a gain of approximately 44%. The move was not a straight line: the shares consolidated near the low-to-mid $60s in early September before breaking higher through the $70s and $80s later in the month.
The 30-day rally is part of a much larger trend. Over the last quarter, the stock has climbed from roughly $38.34 in late June to the current level, an increase of more than 130%. This places TXG near its 52-week high and extends a rebound from a 52-week low of $11.16, a recovery that has been driven by improving sentiment around new product launches, legal wins, and renewed analyst coverage rather than any single earnings report.
What Drove TXG Stock Price in the Last 30 Days
Several verified developments contributed to the sharp move higher. On September 29, 2026, 10x Genomics announced the first commercial shipments of Atera, its next-generation spatial biology platform introduced in April. Atera combines whole-transcriptome analysis, sub-cellular resolution, and single-cell sensitivity at large scale, and the company has said the platform is now moving into the hands of researchers worldwide across discovery, translational, and biopharma applications.
The product momentum was reinforced by a legal victory. A jury found that competitor Parse Biosciences willfully infringed three of 10x Genomics' patents, awarding the company more than $4.8 million in damages and affirming the validity of its intellectual property. The verdict strengthened investor confidence in the company's competitive moat in single-cell and spatial biology.
Analyst activity also fueled the rally. RBC Capital initiated coverage with a Sector Perform rating and a $70 price target in early September; UBS later raised its target to $68 from $20 while maintaining a Neutral rating; Argus initiated coverage with a Buy rating and a $110 target; and Leerink Partners raised its target to $90 from $40 while keeping a Market Perform rating. The company also announced an AI partnership with Lunit focused on oncology biomarker discovery on the Xenium and Atera platforms, aligning the story with broader AI-driven sentiment in life sciences.
What Drove TXG Stock Performance Over the Last Quarter
The quarterly surge reflects a broader re-rating of 10x Genomics as a key supplier of data infrastructure for AI-driven biology. The April introduction of Atera and the launch of Sentira Spatial, a GPU-accelerated cloud analysis suite that shortens data-processing steps for Xenium and Atera users, positioned the company as more than a hardware and reagents vendor, expanding its addressable story into software and cloud workflows.
Large-scale collaborations and public-private initiatives aimed at building biological datasets for AI models have reinforced demand expectations. At the same time, a string of analyst initiations and target increases during the quarter signaled renewed Wall Street attention after a prolonged period of weak sentiment. This narrative-driven repricing occurred even though the company remains unprofitable on a trailing basis, a dynamic that has intensified the debate between momentum and fundamental valuation.
Trending AI Robots
For traders who prefer a systematic, data-driven approach, Tickeron's Trending AI Robots page offers a curated view of AI-powered trading bots. Tickeron provides hundreds of AI trading bots that trade thousands of tickers, but only the top-performing and most relevant bots appear in this curated section, making it easier to surface strategies that are currently attracting attention. These bots vary in strategy, timeframe, and performance metrics, so investors can explore approaches ranging from short-term signals to longer-horizon models. Browsing the section is a practical way to observe how algorithmic tools are navigating momentum-driven names and shifting market conditions.
TXG Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, investors will monitor the ramp of Atera instrument placements and whether early shipments translate into the high-margin consumables pull-through the company expects in 2027. Adoption and monetization of the Sentira Spatial cloud platform, which is anticipated to become a paid, consumption-based service in 2027, will also be closely watched. Earnings reports and updated guidance will be critical, given the company's prior 2026 outlook for 0% to 4% underlying growth.
Macroeconomic factors, including U.S. academic and government research funding and biopharma capital spending, remain key demand drivers. Competitive dynamics in spatial and single-cell markets, ongoing patent litigation, and elevated insider selling are additional risks to track. Finally, given that the stock now trades above the average analyst price target, valuation and the sustainability of momentum will be central to the near-term debate.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Aroon Indicator for TXG shows an upward move is likely
TXG's Aroon Indicator triggered a bullish signal on October 01, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 234 similar instances where the Aroon Indicator showed a similar pattern. In 192 of the 234 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on September 08, 2026. You may want to consider a long position or call options on TXG as a result. In 68 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for TXG just turned positive on September 14, 2026. Looking at past instances where TXG's MACD turned positive, the stock continued to rise in 31 of 45 cases over the following month. The odds of a continued upward trend are 69%.
Following a +2.10% 3-day Advance, the price is estimated to grow further. Considering data from situations where TXG advanced for three days, in 209 of 269 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 16 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
TXG broke above its upper Bollinger Band on September 17, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. TXG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 44 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (13.966) is normal, around the industry mean (10.853). P/E Ratio (0.000) is within average values for comparable stocks, (98.910). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (15.038) is also within normal values, averaging (39.828).
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TXG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a life science technology company, which engages in building products to interrogate, understand and master biology
Industry MedicalNursingServices